AOD-9604 vs clenbuterol: what the human data actually shows

Last updated 2026-07-25

What is AOD-9604 and how is it supposed to work?

AOD-9604 is a synthetic fragment of human growth hormone, built from amino acids 176 to 191 of the HGH molecule. The idea behind it goes back to the observation that this particular tail end of the HGH molecule seems to carry the fat-metabolizing signal without the growth-promoting signal that comes from the rest of the protein. That's the pitch: get the lipolysis (fat breakdown) effect of growth hormone without the downsides of raising IGF-1 or triggering tissue growth. It's a clean idea on paper. The problem is that the human trial record never delivered a clean result to match it. A 2004 review in Current Opinion in Investigational Drugs covering AOD-9604's metabolic profile is one of the few indexed sources that discusses its mechanism directly, and it sits inside a broader 2006 review of obesity drugs then in development that lists AOD-9604 alongside a crowd of other candidates, most of which never reached market ^[1][2]. Being included in a 'drugs in the pipeline' review isn't the same as having a positive phase 3 result. Most compounds in that 2006 list didn't make it to approval either. That context matters. It tells you AOD-9604 wasn't unique in stalling out, it just stalled out too.

What is clenbuterol and how is it supposed to work?

Clenbuterol is a beta-2 adrenergic agonist. It was developed as a bronchodilator, and it's approved in some countries as an asthma treatment for humans and as a treatment for airway disease in horses. It is not approved for human use in the United States for any indication. Its fat-loss reputation comes from its pharmacology: beta-2 agonists increase metabolic rate and can shift substrate use toward fat oxidation, and this effect has been documented for decades in livestock production research, where clenbuterol was used (and then banned) as a repartitioning agent to grow leaner meat in cattle and pigs. That's a real, measurable effect in a real population. It's just not a population of dieting adults. The human data on clenbuterol for fat loss specifically is thin and mostly old, dating to small studies in the 1990s on lean mass and fat mass in specific patient groups, not general population weight-loss trials. Most of what circulates online as 'clenbuterol fat loss studies' either doesn't hold up to a full read or was done in animals.

Did AOD-9604 actually work in human obesity trials?

This is the part most sellers skip, so it's worth saying plainly: AOD-9604 went through human obesity trials, and the weight-loss results did not separate convincingly from placebo. That's the central, unavoidable fact about this compound's human record. The indexed literature on AOD-9604 is sparse and mostly review-level rather than large new phase 3 data. The 2004 metabolic profile review and the 2006 obesity-pipeline review are the main citable sources describing where the compound stood scientifically ^[1][2]. Neither of those describes a trial that produced a clear, replicated, clinically meaningful weight-loss advantage over placebo in humans. Compare that to how strict the bar is for an actual obesity drug approval. Drugs that made it through, like the GLP-1 class, needed placebo-controlled trials with body weight as the primary endpoint and a magnitude of effect big enough to be obvious in the topline numbers. AOD-9604 never produced that kind of data package, and it was never submitted to the FDA for an obesity indication, a fact you can confirm yourself by searching it in the FDA's own drug approval database and finding nothing [Drugs@FDA]. If you want the full detail on what the human trials actually reported, read our AOD-9604 before and after claims piece, which walks through the trial history section by section.

AOD-9604 vs clenbuterol: side-by-side comparison

Here's the honest comparison, not the marketing version.

Neither one is a 'safe alternative' to the other. They're both unapproved-for-this-purpose compounds riding on mechanism stories rather than finished efficacy trials.

Is either one legal to buy in the US?

Neither is FDA approved for weight loss, and that changes what 'legal' even means here. Clenbuterol has no approved human use in the US at all. Selling it as a human drug product is not lawful, and the FDA has never approved it for people; its only lawful US use is as a veterinary bronchodilator for horses under prescription. Buying it for personal fat loss puts you in a gray-to-black market with no quality control at all. AOD-9604 sits in a different, murkier lane. It sometimes shows up through compounding pharmacies, which operate under a specific federal framework: pharmacies compounding under section 503A of the FD&C Act must use bulk drug substances that meet certain criteria, and FDA maintains lists of substances that are and are not permitted for 503A and 503B compounding [21 U.S.C. 353a][21 CFR 216.23][21 CFR 216.24]. Being compoundable isn't the same as being FDA-approved for an indication, and a pharmacy naming a peptide on an ingredient list doesn't mean the FDA has evaluated it for fat loss. Also relevant: FDA's rule on 'intended use' means how a product is marketed, more than its chemical identity, determines its regulatory status [21 CFR 201.128], which is part of why so many peptide sellers use vague research-only language. If a source ever makes it onto FDA's nominated bulk substances list for 503A, that's a document worth checking directly rather than trusting a vendor's claim about it [FDA bulk substances 503A][FDA nominated substances list]. Read our AOD-9604 how to inject piece too if you're weighing sourcing routes; it covers what a legitimate compounding channel should look like in practice, down to how the vial should be labeled.

Does AOD-9604 or clenbuterol show up on a drug test?

Clenbuterol is a established banned substance in competitive sport and shows up on standard anti-doping panels; this isn't controversial or new. AOD-9604 is more interesting technically. A 2013 study in Drug Testing and Analysis specifically examined whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test used to catch growth hormone doping, and found that it does not influence that assay ^[3]. That's a narrow, specific finding: it means AOD-9604 won't cause a false negative or false positive on that particular hGH test, not that AOD-9604 itself is undetectable or permitted. Separately, anti-doping labs have developed specific analytical methods to catch peptides like AOD-9604 directly. Research on detecting peptide drugs and analogs in doping controls has covered exactly this class of compound ^[4][5], and newer screening methods using direct urine injection with liquid chromatography and ion mobility mass spectrometry were built in part to catch small peptides under 2 kDa, a category AOD-9604 falls into ^[6]. If you compete in a tested sport, assume both compounds are visible to a determined lab, regardless of what a seller tells you about 'undetectable' peptides.

What does the safety data say about each?

Clenbuterol's risk profile in humans is well documented from decades of clinical and case-report use as a bronchodilator: tachycardia, palpitations, tremor, and in overdose or contaminated-product cases, serious cardiac events. This isn't a hypothetical. It's the standard pharmacology of a beta-2 agonist at doses well above what's used for asthma. AOD-9604's safety picture in humans is much less mapped out, mostly because the trial record is thin. Recent 2026 reviews looking at peptide therapies used off-label in orthopedic and sports-performance contexts flag this exact problem: many of these peptides, AOD-9604 included, get used clinically or recreationally with far less safety and efficacy data behind them than people assume, and dosing, duration, and long-term risk aren't well characterized ^[7][8]. That's a fair summary of where things stand: not 'proven dangerous,' but 'not well studied,' which is its own kind of risk when you're injecting something regularly for months. Neither compound has a body of long-term human safety data that would satisfy an FDA review for a fat-loss indication. That gap is the story with both of them.

Which one has better evidence: AOD-9604 or clenbuterol?

If you're grading strictly on 'does a placebo-controlled human trial show meaningful fat loss,' neither compound clears that bar convincingly today. AOD-9604 has a defined mechanism story and was pushed through actual obesity-focused development, which at least means there's a documented human trial history to point to, even though that history shows results that didn't separate clearly from placebo ^[1][2]. Clenbuterol has a stronger basic pharmacology case (beta-2 agonism reliably shifts fat oxidation, this is well established in physiology) but a weaker modern human obesity-trial case, because it was never developed as a diet drug in the first place. Its 'evidence' is mostly extrapolated from asthma pharmacology and animal agriculture, not from trials in people trying to lose fat. So the honest ranking is short: clenbuterol has more mechanistic certainty, AOD-9604 has more direct (if disappointing) human trial history. Neither has what you'd call a strong human efficacy case for weight loss specifically.

What has stronger human evidence than either of these?

If the actual goal is fat loss backed by real trial data, there are compounds with much cleaner records than AOD-9604 or clenbuterol, and it's worth naming that plainly rather than pretending these two are the only options. GLP-1 receptor agonists (semaglutide, tirzepatide) have large placebo-controlled trials with body weight as a primary endpoint and effect sizes big enough to drive FDA approval for obesity specifically, something neither AOD-9604 nor clenbuterol has achieved. That's not a peptide-world opinion, it's what's sitting in the FDA's own approved drug database right now [Drugs@FDA]. Within the peptide and growth-hormone-adjacent space specifically, tesamorelin is the one compound with an actual FDA-approved indication (HIV-associated lipodystrophy, specifically for visceral fat reduction), which puts it in a different evidence tier than AOD-9604 entirely. If you're comparing growth-hormone-pathway options, read our AOD-9604 vs tesamorelin comparison before assuming AOD-9604 is the 'gentler' choice; gentler isn't the same as proven.

If someone still wants to try AOD-9604, what should they know first?

Go in with the trial record clear in your head: this is a compound whose own obesity studies didn't separate convincingly from placebo. That's not a reason to panic, but it is a reason to keep expectations low and to be skeptical of any before-and-after story you see online. If you're set on trying it anyway, the two things that actually matter are sourcing and injection practice, not the marketing copy. A provider-reviewed sourcing route through a legitimate compounding pharmacy at least gets you a product that's been checked for identity and sterility, which matters enormously with an injectable. AOD-9604 Co reviews provider options and points readers toward the pharmacy partners that fulfill through that vetted channel, rather than unregulated research-chemical sellers with no quality testing behind them. For the practical side of injecting it correctly (needle size, site rotation, storage), see our AOD-9604 how to inject guide. But don't skip the bigger question first: does the goal justify betting on a compound whose best human trials came back inconclusive against placebo? For the fuller before-and-after evidence review, see AOD-9604 before and after claims.

Frequently asked questions

Is AOD-9604 better than clenbuterol for fat loss?

Neither has strong human trial evidence for fat loss. AOD-9604's own obesity trials didn't beat placebo convincingly. Clenbuterol has real beta-2 agonist pharmacology but almost no modern human weight-loss trial data behind it, since it was developed as a bronchodilator, not a diet drug.

Can you take AOD-9604 and clenbuterol together?

There's no published human trial data on combining them, so any claimed benefit is theoretical. Stacking two compounds with thin individual safety data, one with unclear cardiac effects and one with known cardiac stimulant effects, adds risk without added evidence of benefit.

Is clenbuterol legal to buy in the US?

No, not for human use. Clenbuterol has no FDA-approved human indication in the US; its only approved US use is as a veterinary bronchodilator for horses. Selling it as a human weight-loss product is not a lawful marketing use.

Does AOD-9604 show up on a hormone or steroid blood test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not interfere with the WADA hGH isoform immunoassay, meaning it won't cause a false reading on that specific growth hormone test. Separate peptide-specific detection methods have been developed to catch AOD-9604 directly in anti-doping screening.

Why did AOD-9604 fail in obesity trials if the mechanism made sense?

The fragment rationale (isolating HGH's fat-metabolizing region from its growth-promoting region) is scientifically reasonable, but a good mechanism story doesn't guarantee a clinical effect big enough to beat placebo in real patients. The available reviews of AOD-9604's development don't show a trial that cleared that bar.

What's the difference between AOD-9604 and regular HGH?

AOD-9604 is a small fragment representing amino acids 176-191 of the full HGH molecule, designed to isolate a fat-metabolism effect without triggering the growth-promoting IGF-1 pathway that full-length HGH activates. It is a different molecule with different intended pharmacology, not a milder version of HGH.

Has clenbuterol ever been tested in a real human obesity trial?

Current indexed literature doesn't show a modern, large, placebo-controlled human obesity trial for clenbuterol. Its fat-metabolism reputation comes mainly from beta-2 agonist pharmacology, older small studies in specific patient groups, and extensive (and separately regulated) use as a livestock repartitioning agent.

Is AOD-9604 approved by the FDA for weight loss?

No. AOD-9604 has no FDA-approved indication for weight loss or any other use; searching the FDA's own Drugs@FDA database returns no approved product by that name. It sometimes appears through compounding pharmacies operating under section 503A rules, which is a different regulatory status than approval.

What are the main side effects of clenbuterol?

Clenbuterol's known human effects include tachycardia, palpitations, tremor, and anxiety, consistent with its action as a beta-2 adrenergic agonist. In overdose or with contaminated product, serious cardiac events have been reported. These effects are well documented from its use as a bronchodilator, not from fat-loss-specific trials.

Is there a peptide with better proven fat-loss data than either of these?

Tesamorelin has an actual FDA-approved indication for reducing visceral fat in HIV-associated lipodystrophy, giving it a stronger evidence tier than AOD-9604. GLP-1 drugs like semaglutide have large placebo-controlled obesity trials behind their FDA approvals, well beyond what either AOD-9604 or clenbuterol has produced.

Why do people still buy AOD-9604 if the trials didn't show results?

Mostly because of persistent online before-and-after marketing and the appeal of the fragment mechanism story, not because of strong recent trial data. The actual human obesity trial record shows results that didn't separate convincingly from placebo, a fact often left out of sales copy.

Can AOD-9604 or clenbuterol cause a positive doping test?

Clenbuterol is a long-banned substance in competitive sport and is directly tested for. AOD-9604 doesn't interfere with the standard WADA hGH isoform test, but dedicated peptide-detection methods exist specifically to catch AOD-9604 and similar small peptides in anti-doping screening.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604's metabolic profile and mechanism are described in this 2004 review, one of the few indexed sources on its development.
2. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 appears in a 2006 review of obesity drugs then in clinical development, alongside many candidates that never reached approval.
3. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing.
4. PubMed, Expert Review of Proteomics (2014): Anti-doping science has developed specific detection approaches for peptide drugs and analogs including compounds like AOD-9604.
5. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical methods for detecting emerging non-approved therapeutics in doping controls cover peptide compounds in this class.
6. PubMed, Journal of Separation Science (2016): Newer screening methods using direct urine injection and ion mobility mass spectrometry were built to catch peptides under 2 kDa, a category including AOD-9604.
7. PubMed, Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews (2026): Recent review of therapeutic peptides in orthopedics flags gaps in safety and efficacy data for peptides used off-label, including compounds like AOD-9604.
8. PubMed, Sports Medicine (2026): Review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance highlights unclear safety and efficacy data for unapproved peptides.
9. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances permitted for use in compounding under section 503A of the FD&C Act.
10. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances permitted for use in outsourcing facility compounding under section 503B.
11. Cornell Law School, 21 U.S.C. 353a: Establishes the federal statutory framework under which pharmacies may compound drugs under section 503A.
12. eCFR, 21 CFR 201.128: Defines how a product's marketing and labeling, more than its chemical identity, determines its regulatory 'intended use' status.
13. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains FDA's process for evaluating and listing bulk substances eligible for 503A compounding.
14. FDA, Bulk Drug Substances Nominated for Use in Compounding: FDA maintains a current list of nominated bulk substances under review for 503A compounding eligibility.
15. FDA, Drugs@FDA database: Confirms neither AOD-9604 nor clenbuterol has an FDA-approved indication for weight loss, while GLP-1 drugs do have approved obesity indications.